We have been representing patients and their family in drug injury lawsuits for the past 16 years and this is our main practice area.
Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.
Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.
Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.
We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.
If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.
We encourage you to submit a Drug Injury Case Review — it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.
While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.
It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Legal & Medical News: Featured Article
On October 13, 2016 attorneys for Bristol-Myers Squibb Company and Pfizer Inc. filed with the United States Judicial Panel on Multidistrict Litigation (JPML) this court document, “BRISTOL-MYERS SQUIBB COMPANY AND PFIZER INC.’S MOTION FOR TRANSFER OF RELATED ELIQUIS (APIXABAN) PRODUCTS LIABILITY ACTIONS FOR COORDINATED PRETRIAL PROCEEDINGS PURSUANT TO 28 U.S.C. § 1407, which will refer to as “Defendants’ MDL Motion” hereafter.
As for why these two drug companies think that Eliquis lawsuits filed in the federal court system should be consolidated as a Multidistrict Litigation (MDL) case, we get this statement from the aforementioned Defendants’ MDL Motion:
While the claims vary slightly among the various complaints, the crux of the Related Actions is that each Plaintiff experienced bleeding while taking Eliquis, and that Defendants should be held liable for Plaintiffs’ injuries under a variety of theories, including that: (1) Defendants failed to warn adequately about the risk of bleeding; and (2) Defendants should not have sold Eliquis without precautions for blood monitoring or an additional drug to reverse its anticoagulant effect. Thus, Plaintiffs’ claims are based on a common set of core facts.
In a separate court document, “BRISTOL-MYERS SQUIBB COMPANY AND PFIZER INC.’S MEMORANDUM OF LAW IN SUPPORT OF THEIR MOTION FOR TRANSFER OF RELATED ELIQUIS (APIXABAN) PRODUCTS LIABILITY ACTIONS FOR COORDINATED PRETRIAL PROCEEDINGS PURSUANT TO 28 U.S.C. § 1407”, the two drug companies suggest to the JPML that this possible Eliquis MDL be assigned to U.S. District Judge Lewis A. Kaplan of the Southern District of New York.
It is currently anticipated that the Defendants’ MDL Motion will be considered by the JPML at the upcoming hearing session scheduled for January 26, 2017, in Miami, Florida.
Be assured we will be watching for the JPML’s determinations about the requested creation and suggested assignment of this federal court Eliquis MDL case.
- Is Eliquis A Safe Alternative To Warfarin For Patients On Dialysis?
- To Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet
- Viagra – Melanoma MDL Might Include Cialis Lawsuits And Levitra Cases
- Risk of Hepatitis B Reactivation Associated With Gleevec And Iclusig
- Black-Box Warning For Harvoni, Sovaldi, Viekira Pak: Hepatitis B Risk
- September 2016 Savaysa Label Change Points Out There Is Still No Antidote
- Fosamax – Femur Fracture Lawsuits Wait On Rulings By Court Of Appeals